---
schema_version: "secwatch.filing_event.v1"
accession: "0001447362-22-000010"
form_type: "8-K"
ticker: "CSTL"
cik: "0001447362"
company_name: "CASTLE BIOSCIENCES INC"
filed_at: "2022-01-10T23:59:59+00:00"
generated_at: "2026-06-27T19:19:48.845582+00:00"
event_type: "earnings"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Castle Biosciences expects FY 2021 revenue to meet or exceed $89-93M guidance; test volumes up 55%

## Summary
- FY2021 revenue expected at or above guided $89-93M; year-end cash ~$330M.
- Total gene expression profile test reports delivered in 2021: 28,118 (+55% YoY).
- DecisionDx-Melanoma reports up 25% YoY to 20,328 despite 11% drop in melanoma diagnoses vs pre-COVID.
- DecisionDx-SCC reports grew to 3,510 in 2021 from 485 in 2020; Q4 2021: 1,265 (+196%).
- myPath/DecisionDx DiffDx-Melanoma reports: 2,662 in 2021 vs 73 in 2020; Q4: 904 vs 73.

## SEC filing metadata
- accession: 0001447362-22-000010
- form_type: 8-K
- ticker: CSTL
- cik: 0001447362
- company_name: CASTLE BIOSCIENCES INC
- filed_at: 2022-01-10T23:59:59+00:00
- event_type: earnings
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 2.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1447362/000144736222000010/0001447362-22-000010-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1447362/000144736222000010/cstl-20220110.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001447362-22-000010
- JSON: https://secwatch.observer/filing/0001447362-22-000010.json
- Plain text: https://secwatch.observer/filing/0001447362-22-000010.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.